Kisspeptin-10

Status Not approved as a standalone drug; studied as an investigational IVF trigger and reproductive-axis probe under kisspeptin-54Best evidence E3Sources checked 2026-09-18

Kisspeptin-10 is the short bioactive fragment of an endogenous reproductive hormone. Real human trials exist for this hormone family, including a Phase 2 IVF trigger trial with a 95% oocyte maturation rate, but almost all of the substantial trial work used the longer-acting kisspeptin-54, not kisspeptin-10 specifically.

What it is

Kisspeptin is an endogenous human peptide hormone that sits upstream of GnRH in the reproductive hormone cascade, stimulating the hypothalamus to release GnRH, which in turn drives LH and FSH secretion. The full-length hormone (kisspeptin-54) is cleaved into shorter fragments, including kisspeptin-10, the shortest fragment retaining full receptor-binding activity. Kisspeptin-10 has an extremely short plasma half-life, on the order of a few minutes, shorter than kisspeptin-54’s.

The human trial record, and which form was actually used

This is important to state precisely: most of the substantial human trial work on kisspeptin, run mainly by groups at Imperial College London and Massachusetts General Hospital, used kisspeptin-54, not kisspeptin-10, specifically because the longer fragment’s somewhat longer half-life makes it more practical to dose.

A Phase 2, multi-dose, open-label, randomized trial in 60 women at high risk of ovarian hyperstimulation syndrome (OHSS) during IVF used a single injection of kisspeptin-54, at doses from 3.2 to 12.8 nmol/kg, to trigger oocyte maturation as an alternative to hCG or GnRH agonist triggers; oocyte maturation occurred in 95% of women, live birth rates reached 45% overall (62% at the 9.6 nmol/kg dose), and no woman developed moderate, severe or critical OHSS.

A separate study in eight healthy postmenopausal women used a continuous 24-hour kisspeptin-54 infusion (12.5 mcg/kg/h) to probe how circulating estradiol modulates kisspeptin-stimulated LH pulsatility, finding that postmenopausal women were largely resistant to kisspeptin’s stimulatory effect unless given estradiol replacement.

Kisspeptin-10 specifically has been used in earlier, smaller mechanistic dose-response and bolus-injection studies establishing that it raises LH and testosterone in men and stimulates the reproductive axis in both sexes, but the larger, better-powered trials with clinical outcomes (the IVF trigger trial, the postmenopausal infusion study) used kisspeptin-54.

What is not established

Whether findings from kisspeptin-54 trials, including the IVF trigger and postmenopausal infusion studies, transfer directly to kisspeptin-10, given the shorter fragment’s even shorter half-life and the studies’ use of continuous infusion or single supervised injections rather than a periodic self-administered subcutaneous shot.

Any established dose, frequency or indication for kisspeptin-10 specifically outside a supervised research or fertility-clinic setting. No trial reviewed for this entry tested a general “reproductive health” self-injection protocol.

What is not known

Whether findings from kisspeptin-54 trials transfer directly to kisspeptin-10, given the shorter fragment’s even shorter plasma half-life.

Any established dose, frequency or indication for kisspeptin-10 specifically outside a supervised research or fertility-clinic setting.

Doses used in published research

No published study has administered this compound to a human being, so no dose appears in the literature and none has been established.

Amounts above record what a named source reported administering in a study. They are not a recommendation, not a protocol, and not instructions.

Converting a vial and a syringe into a draw volume is a separate, mechanical question from what amount to use. The reconstitution calculator does that arithmetic for peptide, HCG, and HGH vials.

What circulates E5

Figures reported online. Not dosing, not verified, not endorsed.
Reported use	Route	Amount reported	Frequency	Reported length
Reproductive/hormonal support, general	Subcutaneous	100 to 250 mcg per dose	Once or twice daily	Ongoing

Circulating dosing for kisspeptin-10 describes 100 to 250 micrograms subcutaneously, once or twice daily. The controlled human trials this hormone family has actually been studied under used kisspeptin-54 by continuous IV infusion or a single clinic-administered injection dosed by body weight (nmol/kg), not a fixed microgram amount of the shorter, faster-clearing kisspeptin-10 given by daily self-injection. The circulating regimen does not match the pharmacology of the compound the trials were actually run on.

Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.